N-Acetyl Selank Amidate
Research OnlyAlso known as: NA-Selank, N-Acetyl Selank, Acetyl-Selank-Amidate, NASA
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.
Research Statistics
N-acetyl amidate modification of selank with no direct human studies; mechanism extrapolated entirely from parent compound with no independent validation of this specific modification.
Research Dossier
Overview
What is N-Acetyl Selank Amidate and what does the research say?
Mechanism of Action
The proposed mechanisms of N-Acetyl Selank Amidate are extrapolated entirely from the parent compound Selank. No direct research exists on this specific modification.
How It Works (Simplified)
N-Acetyl Selank Amidate is theorized to work through the same pathways as Selank, with potentially enhanced stability:
Proposed to enhance GABA-A receptor sensitivity, promoting inhibitory neurotransmission and anxiolytic effects (based on Selank data).
Theorized to inhibit enkephalinase, preserving endogenous opioid peptides involved in mood and stress response.
Proposed to upregulate brain-derived neurotrophic factor, potentially supporting neuroplasticity and cognitive function.
N-acetylation and C-amidation theoretically protect against aminopeptidase and carboxypeptidase degradation, extending half-life.
Scientific Pathways
GABAergic Pathway (Anxiolytic - Theoretical)
NA-Selank-Amidate → GABA-A receptor modulation → Enhanced inhibitory signaling
↓
Reduced anxiety (proposed)Enkephalin Pathway (Mood - Theoretical)
NA-Selank-Amidate → Enkephalinase inhibition → Preserved endogenous enkephalins → Mood effectsKey Research: No direct studies exist on N-Acetyl Selank Amidate. Parent compound data from Zozulia AA et al. (2008) demonstrated Selank anxiolytic effects. PMID:18577768
Important Limitations
- Zero published studies on N-Acetyl Selank Amidate specifically
- All mechanisms extrapolated from parent compound Selank
- Modifications may alter or eliminate biological activity
- Human pharmacokinetics completely unknown
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on parent compound data: Users report initial anxiolytic effects within days. No pharmacokinetic data exists for NA-Selank-Amidate to confirm onset timing.
Theoretical continued GABAergic modulation and enkephalin protection. Parent compound studies suggest sustained anxiolytic effects with continued use.
Long-term effects completely unknown. No studies on extended use of either Selank or NA-Selank-Amidate beyond short-term trials.
No data available. Human pharmacokinetics, tolerance development, and optimal treatment duration are completely unknown for this modification.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate N-Acetyl Selank Amidate product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining N-Acetyl Selank Amidate with other peptides. Based on published research and mechanistic considerations.
Selank
SynergisticParent compound with identical core sequence. NA-Selank-Amidate may have improved stability but shares the same mechanisms. No studies on combining the two forms.
Na-Semax-Amidate
CompatibleBoth are modified Russian nootropic peptides targeting different pathways. Semax focuses on BDNF/NGF while Selank emphasizes GABAergic modulation. Commonly stacked in nootropic protocols.
Semax
CompatibleDifferent mechanisms of action. Semax targets neurotrophic factors while Selank focuses on anxiolytic pathways. No known contraindications.
Dihexa
CautionBoth target cognitive pathways through different mechanisms. Limited safety data on combination. Exercise caution due to lack of interaction studies.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare N-Acetyl Selank Amidate
Related Peptides
Alixorexton
ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum, Polypeptide brain extract, Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.